1. New research identifies three distinct clinical clusters of systemic lupus erythematosus (SLE) patients, providing insights into disease trajectories and outcomes.
2. The study reveals stable phenotypic clusters associated with specific autoantibody profiles and prognoses.
3. Over half of Cluster 3 patients transitioned to a different subgroup during follow-up.
4. The mean follow-up period was 13.1 ± 10.0 years, providing substantial longitudinal data to analyze disease progression and stability of the identified clusters. The research may help explain the heterogeneity of treatment responses among SLE patients and optimize therapeutic decisions for personalized medicine.

Source: RMD Open